IPCA Labs: MCap - Rs 25,823 crore I CMP - Rs 2035.7 crore I PAT FY21 - Rs 1140 crore
HDFC Securities cites certain reasons for the positive approach towards IPCA Labs. They are as follows - strong volume growth in domestic formulation across therapeutic areas, cost-competitive and consistent quality driving better business prospects in API segment, robust debt-free B/S and strong return ratios and better traction in the international markets such as Europe and Asia. Source: ipca.com
HDFC Securities cites certain reasons for the positive approach towards IPCA Labs. They are as follows - strong volume growth in domestic formulation across therapeutic areas, cost-competitive and consistent quality driving better business prospects in API segment, robust debt-free B/S and strong return ratios and better traction in the international markets such as Europe and Asia. Source: ipca.com
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.